Business Context and Reporting Period
This Form 8-K was filed by Platform Specialty Products Corporation on January 12, 2015. The filing serves as a voluntary disclosure of financial information related to the completed acquisition of Chemtura AgroSolutions (the "CAS Acquisition") and provides pro forma financial data incorporating the proposed acquisition of Arysta LifeScience Limited and the completed acquisition of MacDermid Holdings, LLC.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Instead, it references the following exhibits which contain the detailed financial data:
- Exhibit 99.1: CAS audited combined balance sheets (Dec 31, 2013 and 2012) and statements of income and cash flows for the two-year period ended Dec 31, 2013.
- Exhibit 99.2: CAS Management's Discussion of Operations and Cash Flows for fiscal years 2013 and 2012, and unaudited nine-month periods ended Sept 30, 2014 and 2013.
- Exhibit 99.3: CAS unaudited combined carve-out interim financial statements (balance sheet as of Sept 30, 2014; income and cash flow statements for the nine months ended Sept 30, 2014 and 2013).
- Exhibit 99.4: Platform's unaudited pro forma combined consolidated balance sheet (Sept 30, 2014) and statement of operations (nine months ended Sept 30, 2014 and year ended Dec 31, 2013), giving effect to the CAS, Arysta, and MacDermid acquisitions and related financings.
Material Changes
The primary material change disclosed is the completion of the acquisition of Chemtura AgroSolutions, previously announced and detailed in an 8-K filed on November 3, 2014. The filing also highlights the inclusion of pro forma data reflecting the proposed Arysta Acquisition and the completed MacDermid Acquisition (closed October 31, 2013).
Guidance, Outlook, and Risks
The filing text does not contain specific management commentary, forward-looking guidance, or a discussion of risks and contingencies. It strictly serves to incorporate by reference the financial statements and management discussion found in the attached exhibits.
Investor Verification Checklist
- Review Exhibit 99.2 for CAS Management's discussion of operations and cash flows to understand the acquired business's performance trends.
- Analyze Exhibit 99.3 for the unaudited carve-out financials of CAS as of September 30, 2014, to assess the most recent standalone performance of the acquired unit.
- Examine Exhibit 99.4 to evaluate the pro forma financial impact of combining Platform, CAS, Arysta, and MacDermid, specifically regarding debt levels and consolidated profitability.
- Verify the status of the proposed Arysta LifeScience Limited acquisition, as the pro forma data assumes its completion.